Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic approach in Colchicine-resistant Recurrent Pericarditis in children (Anakinra vs steroids)
2023-504756-96-00Phase 3Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Oct 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in recurrent pericarditis and idiopathic recurrent pericarditis (IRP) comparing Anakinra arm with Prednisone arm (2 arms). Primary endpoints: Complete response of disease flare at day 7 and Lack of relapse at month 3. Planned start Oct 2023; status: authorised.
02
Drugs
anakinraprednisone
03
Conditions
recurrent pericarditisidiopathic recurrent pericarditis (IRP)
Beyond the preview
Go deeper on 2023-504756-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504756-96-00.